U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: September 15, 1996
Commission file number 0-19866
CELOX LABORATORIES, INC.
(Exact name of small business issuer as specified in its charter)
MINNESOTA 36-3384240
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
856 SOUTH FIFTH STREET, HOPKINS, MINNESOTA 55343
(Address of principal executive offices) (Zip code)
Issuers telephone number, including area code: (612) 933-2616
Item 5. Delisting of Shares from NASDAQ SmallCap Market
On August 14, 1996 the Company issued the attached press release which
disclosed that the Company had received notice from NASDAQ that it failed to
meet the requirements for continued listing on the NASDAQ SmallCap Market. On
August 15, 1996 the Company's shares of Common Stock began trading in the OTC
Market.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Celox Laboratories, Inc.
September 15, 1996 By /s/ Milo R. Polovina
------------------------------------
Milo R. Polovina, President
CELOX
Contact: Milo R. Polovina, Chairman and CEO
David E. Tess, Vice President Finance and Administration
Date: August 14, 1996
FOR IMMEDIATE RELEASE Celox Laboratories, Inc. Announces Delisting Notice from
NASDAQ
HOPKINS, Minn, August 14, 1996-CELOX Laboratories, Inc. (NASDAQ: CELX) today
announced that it has received notice from NASDAQ that the Company fails to meet
the requirements for continued listing on the NASDAQ SmallCap Market.
Specifically, the Company does not currently meet the required level of total
assets needed to continue to be listed. As a result, the Company will be
delisted from the NASDAQ SmallCap Market effective with the close of business on
August 14, 1996.
Beginning August 15, 1996 the Company's securities will be traded in the OTC
Market.
Celox management is currently in the process of developing a strategic plan
which will bring the Company back into compliance with the listing requirements.
In other news, the Company announced the filing of documents needed for an
International Patent Application for its ViaStem(TM) product as required by the
Patent Cooperation Treaty. ViaStem(TM) was developed to improve the preservation
of critical cells (e.g. stem Cells) which are required for bone marrow
transplantation. Other potential applications for ViaStem(TM) include the
preservation of umbilical cord blood and platelets.
CELOX Laboratories, Inc. is a biotechnology company that specializes in
improving the physiological condition of human cells and cells from other
species. CELOX pioneered the development of non-serum cell biology products used
in researching and developing diagnostics and therapeutics for major health
problems such as AIDS and cancer. The Company's products are marketed to major
academic medical centers, biotechnology and pharmaceutical companies.
#####
